GlaxoSmithKline is temporarily halting nationwide production of some of its Excedrin products, ABC affiliate WSYR reported.
The drugmaker is halting production of Excedrin Extra Strength and Excedrin Migraine. A spokesperson told WSYR the halt is due to "inconsistencies in how we transfer and weigh ingredients for Excedrin Migraine caplets and geltabs."
"Based on the available data, GSK believes that the product does not pose a safety risk to consumers. However, as a precautionary measure, GSK Consumer Healthcare has voluntarily implemented a discontinuation of production and distribution," the spokesperson said.
The drugmaker said it does not know when it will resume production of the two drugs it's halting, but other Excedrin products are available.
Some pharmacies in Central New York are already running out of the discontinued Excedrin products, WSYR reported.
Read the full article here.